Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Strides Pharma...

    Strides Pharma appoints former Cipla Chief Operating Officer Dr R Ananthanarayanan as new CEO, MD

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-09T09:30:27+05:30  |  Updated On 9 Jan 2020 9:30 AM IST

    Until joining Strides Pharma, Dr R Ananthanarayanan was the Global Chief Operating Officer at Cipla Limited.


    Bangalore: Strides Pharma Science Limited (Strides) recently announced that the Board of Directors (Board) of the Company have appointed Dr R Ananthanarayanan as Chief Executive Officer (CEO) and Managing Director (MD) of Strides effective January 09, 2020.


    Dr R Ananthanarayanan (Ananth) will succeed Arun Kumar, Founder, and the incumbent CEO & MD of the Company. Arun will transition his active responsibilities at Strides by the financial year ending March 31, 2020, and will step into a strategic role as Chairman of the Board with effect from April 01, 2020.


    Ananth brings with him over three decades of top pedigree global pharmaceutical experience across both the technical and commercial functions. Until recently, Ananth was the Global Chief Operating Officer at Cipla Limited, where he was responsible for the company’s generics business in regulated markets and branded generics in emerging markets. He was also driving their API business, biosimilars, complex drug-device combinations, including 505(b)(2) products.


    Prior to Cipla, Ananth was the President & CEO of Global APIs, Biologics, & Medis Generics B2B division at Teva Pharmaceutical Industries Ltd in the US, managing multi-billion P&L responsibility. He has also held leadership roles at Dr Reddy’s Laboratories, Piramal Healthcare (Formerly Nicholas Piramal), Galpharm International, UK (Acquired by Perrigo Group), and Zydus Cadila.


    Ananth is a Graduate in Pharmaceutical Sciences and earned his PhD in Pharmaceutical Technology from the University of Mumbai, India. He has also been a member of the Board of Advisors at the School of Pharmacy and Health Sciences at Fairleigh Dickinson University, New Jersey.


    Ananth’s appointment at Strides comes at the time when the company has concluded its reset strategy to drive profitable future growth on the back of a stronger balance sheet. The Board strongly believes that Ananth’s exceptional global techno-commercial experience and leadership stature in managing the P&Ls of large global pharmaceutical companies will multiply the company’s commitment to creating perpetual value for all its stakeholders.


    Expressing confidence in the Board’s choice, Arun Kumar, remarked, “Having founded Strides and led the company for close to 30 years, I believe the time is right for me to step aside and have Ananth lead it to greater heights. Ananth brings in the right balance of technical and commercial expertise and I am confident that Strides will significantly benefit from his leadership experience, industry perspective, technical knowledge, and business acumen. As he takes on the mantle of Strides, I will now move to a more strategic role as the Chairman of the Board and will dedicate time to Strides' newly announced investments in Biotech and sterile injectables.”


    Dr R Ananthanarayanan, the new CEO & MD of Strides, commented, “It's my privilege and honour to take over as the CEO &MD of Strides, and I would like to appreciate the confidence reposed in me by Arun and the Board. These are exciting times for Strides, and I look forward to partner with all the global colleagues to ensure successful realization of the Strides strategic objectives while ensuring that we consistently deliver quality medicines to all our patients globally.”


    Also Read: Transasia Bio-Medicals names Medtronic biz director Ravi Kaushik as new CEO

    CEOCiplaDr Reddy'sManaging directorpharmapharma newsPiramalR AnanthanarayananStridesStrides PharmaZydus Cadila

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok